http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103735550-B

Outgoing Links

Predicate Object
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-205
filingDate 2013-12-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2015-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2015-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-103735550-B
titleOfInvention A kind of pharmaceutical composition and application thereof for the treatment of chronic kidney disease myocardial damage
abstract The present invention relates to a kind of pharmaceutical composition and application thereof for the treatment of chronic kidney disease myocardial damage.Described pharmaceutical composition contains levocarnitine and trimetazidine, and the weight ratio of levocarnitine and trimetazidine is (77-81): 1, preferred 80:1, and it is also containing conventional pharmaceutical carrier.The present invention by different proportion levocarnitine and trimetazidine coupling under the specific dosage of research for the CKD rat heart, renal function and tissue pathologies change, and it is on the impact of energy metabolism of myocardial, find levocarnitine, trimetazidine weight ratio is at (77-81): plump to CKD rat left ventricle rear wall in the scope of 1, it is the most obvious that Myocardial Interstitial Fibrosis improves effect, the energy metabolism of CKD rat heart muscle significantly improves, inflammation, oxidative stress also significantly improves, heart pathological score and Pathological GSI, TIS scoring significantly declines, thus significantly reduce chronic kidney disease myocardial damage.
priorityDate 2013-12-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ92452
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10917
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419588607
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419526858
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419547245
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID444493
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419589374
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID22227373
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCO01945
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419575953
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID3032
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP13006
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24341
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID61365
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID137319715
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID281811
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419491273
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2707
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID3878934
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1152
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID21109
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID451186576
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP81156
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID231086
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419554682
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID171155
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID451822344

Total number of triples: 39.